Wednesday, May 21 2025 | Time 15:39 Hrs(IST)
Business EconomyPosted at: May 20 2025 7:07PM


Torrent Pharma Q4 revenue pc, net profit rises 11 pc

Ahmedabad, 20 May (UNI) Torrent Pharmaceuticals Limited on Tuesday announced its financial results for the fourth quarter and full year ended 31 March 2025, reporting steady growth across key metrics.
For Q4 FY25, the company posted revenue of Rs 2,959 crore, marking an 8 percent year-on-year increase. Gross margin remained stable at 75.3 percent. Operating EBITDA rose 9 percent to Rs. 964 crore, while net profit after tax climbed 11 percent to Rs. 498 crore. Adjusted for exceptional items and inventory revaluation, operating EBITDA stood at Rs. 981 crore, an 11 percent rise.
For the full fiscal year, Torrent reported revenues of Rs 11,516 crore, up 7 percent from the previous year. Operating EBITDA grew 10 percent to Rs. 3,721 crore, with net profit reaching Rs 1,911 crore, reflecting a 15 percent increase after adjustments for exceptional items.
The company’s India business continued its robust performance with Q4 revenues of Rs 1,545 crore, growing 12 percent and outperforming the Indian Pharmaceutical Market (IPM) growth of 8 percent. Torrent’s chronic therapy segment expanded 14 percent compared to 9 percent IPM growth. The company holds 21 brands in the Top 500 IPM brands, including 14 brands with sales exceeding Rs 100 crore.
In Brazil, revenues declined 6 percent to Rs. 351 crore, primarily due to the depreciation of the Brazilian Real. However, constant currency revenues increased by 5 percent. Torrent’s Brazil operations grew 13 percent compared to a 7 percent market growth. Germany revenues rose 2 percent to Rs. 286 crore, supported by new tender wins and cost efficiency initiatives. The US market recorded a 15 percent revenue growth in Q4 to Rs. 302 crore, with constant currency growth at 10 percent.
Torrent has declared an interim dividend of Rs. 26 per equity share (face value Rs. 5). The Board has recommended a final dividend of Rs. 6 per share, subject to shareholders’ approval.
In a strategic leadership move, Torrent’s Board approved the appointment of Aman Mehta as Managing Director, effective 1 August 2025, as part of its long-term succession planning.
Torrent Pharmaceuticals, the flagship entity of the Torrent Group, ranks seventh in the Indian pharmaceutical market and holds leadership positions in cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology segments.
The company operates in over 50 countries, runs eight manufacturing facilities including five USFDA-approved plants, and maintains a strong focus on R&D with over 750 scientists.
UNI BDN GNK
Tags: #Torrent Pharma Q4 revenue pc# net profit rises 11 pc
More News

TCS receives Rs 2,903 22 crore Advance Purchase order from BSNL

21 May 2025 | 3:33 PM

Hyderabad, May 21 (UNI) The Tata Consultancy Services Limited has received an
add-on Advance Purchase Order (APO) for Rs 2,903.22 crore, inclusive of taxes from
Bharat Sanchar Nigam Limited (BSNL).

see more..

Indian Glove Manufacturers Industry urges implementation of QCO to protect public health

21 May 2025 | 3:05 PM

Hyderabad, May 21 (UNBI) Indian glove manufacturers' Industry (IGMI) on Wednesday urged for a timely implementation of the Quality Control Order (QCO) to protect public health from the risks posed by poor-quality medical gloves.

see more..
Bharat Biotech’s oral cholera vaccine Hillchol demonstrates success in Phase III

Bharat Biotech’s oral cholera vaccine Hillchol demonstrates success in Phase III

21 May 2025 | 2:11 PM

Hyderabad, May 21 (UNI) Bharat Biotech’s Oral Cholera Vaccine Hillchol has demonstrated
against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and
children, supporting its potential as an effective OCV.

see more..

FanCode collaborates with Sony LIV to revolutionise Roland Garros 2025

21 May 2025 | 1:49 PM

Mumbai, May 21 (UNI) FanCode has collaborated with Sony LIV for Roland Garros 2025 coverage and along with them stream all the action from every single court, ensuring that tennis enthusiasts don’t miss a single serve, volley, or match point.

see more..
Rupee opens steady at 85 60 against USD

Rupee opens steady at 85 60 against USD

21 May 2025 | 10:21 AM

Mumbai, May 21 (UNI) The Rupee on Wednesday was seen flat to open at 85.60 on selling of US Dollar by bankers and exporters at the Forex Market informed.

see more..